MAZE (Maze Therapeutics) Total Equity: $341.70 Mil (As of Mar. 2026)


MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $29.84
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics Total Equity?

Maze Therapeutics MAZE +2.90% 14 Total Equity is $341.70 Mil as of Mar. 2026. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Maze Therapeutics's total equity for the quarter that ended in Mar. 2026 was $341.70 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Maze Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Maze Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maze Therapeutics Total Equity Chart

Maze Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Equity
-282.46 -373.85 -311.18 354.97

Maze Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 292.07 262.24 379.44 354.97 341.70
MAZE
14GF Score
Maze Therapeutics Inc MAZE
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Maze Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=397.127-42.161
=354.97

Maze Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=419.71-78.009
=341.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $341.70 Mil mean?
Maze Therapeutics (MAZE) has a Total Equity of $341.70 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Maze Therapeutics and its competitors.
Is Maze Therapeutics' Total Equity too high?
Maze Therapeutics' current Total Equity is $341.70 Mil. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Total Equity compare to AVBP and DMRA?
Maze Therapeutics' Total Equity of $341.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Maze Therapeutics and its competitors. Maze Therapeutics's current Total Equity is $341.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Total Equity of $341.70 Mil. The current Total Equity is $341.70 Mil. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Total Equity is $341.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.84
Price